

## **Eastman Chemical (EMN)**

**\$63.56** (Stock Price as of 12/19/2025)

Price Target (6-12 Months): **\$50.00** 

Long Term: 6-12 Months | Zacks Recommendation: Underperform

(Since: 06/25/25)

Prior Recommendation: Neutral

Short Term: 1-3 Months Zacks Rank: (1-5)

Zacks Style Scores:

Value: A Growth: F Momentum: F

4-Sell

VGM: D

2026 E

### **Summary**

Eastman Chemical's adjusted earnings and sales for the third quarter missed the respective Zacks Consensus Estimates. Soft demand in certain markets will likely affect its volumes. The company remains exposed to weak demand in building & construction and cautious customer behavior in consumer durables and electronics. The Advanced Materials and Additives & Functional Products segments also face headwinds from the impacts of tariffs in the fourth quarter in China and the automotive markets. Eastman also faces headwinds from costs associated with actions to reduce inventories. Higher raw material and energy costs are also expected to weigh on its margins in 2025. The Fibers unit also faces volume pressures from customer inventory destocking.

## Price, Consensus & Surprise<sup>(1)</sup>




#### **Data Overview**

52 Week High-Low	\$103.82 - \$56.11
20 Day Average Volume (sh)	1,744,639
Market Cap	\$7.3 B
YTD Price Change	-30.4%
Beta	1.24
Dividend / Div Yld	\$3.36 / 5.3%
Industry	<b>Chemical - Diversified</b>
Zacks Industry Rank	Bottom 15% (204 out of 243)

# Sales W////W/

Sales and EPS Growth Rates (Y/Y %)(2)



2022 A 2023 A 2024 A 2025 E

Earnings ESP	-10.4%
Expected Report Date	01/29/2026
EPS F1 Est- 4 week change	-1.4%
Last Sales Surprise	-1.8%
Last EPS Surprise	-3.4%

P/E TTM	9.8
P/E F1	11.5
PEG F1	-0.9
P/S TTM	0.8

•				
Q1	Q2	Q3	Q4	Annual*
2,138 E	2,252 E	2,247 E	2,123 E	8,759 E
2,290 A	2,287 A	2,202 A	2,020 E	8,799 E
2,310 A	2,363 A	2,464 A	2,245 A	9,382 A
	2,138 E 2,290 A	2,138 E 2,252 E 2,290 A 2,287 A	2,138 E 2,252 E 2,247 E 2,290 A 2,287 A 2,202 A	2,138 E 2,252 E 2,247 E 2,123 E 2,290 A 2,287 A 2,202 A 2,020 E

## EPS Estimates<sup>(2)</sup>

	Q1	Q2	Q3	Q4	Annual*
2026	1.15 E	1.59 E	1.75 E	1.51 E	6.01 E
2025	1.91 A	1.60 A	1.14 A	0.89 E	5.54 E
2024	1.61 A	2.15 A	2.26 A	1.87 A	7.89 A

<sup>\*</sup>Quarterly figures may not add up to annual.

Sales Estimates (millions of \$)(2)

<sup>(1)</sup> The data in the charts and tables, except the estimates, is as of 12/19/2025.

<sup>(2)</sup> The report's text, the analyst-provided estimates, and the price target are as of 11/25/2025.

### Overview


Eastman Chemical Company, based in Kingsport, TN, manufactures and sells chemicals, plastics and fibers. The company has 16 manufacturing sites in the United States, Europe and Asia-Pacific, supplying products throughout the world.


The company's products include additives, specialty polymers and other raw materials that are integral to the production of paints and coatings, inks, adhesives and other formulated products. It also makes intermediates based on acetyl and oxo chemistries and other intermediate products.

Eastman Chemical's other products include performance chemicals, highly specialized copolyesters and cellulosic plastics, copolyester cellulosic based products, acetate tow and triacetin plasticizers, and natural and solution-dyed acetate yarns. The company recorded revenues of around \$9.4 billion in 2024.

The company has restructured its reporting segments and currently has four business segments - Advanced Materials (32% of 2024 sales), Additives and Functional Products/AFP (31%), Chemical Intermediates (23%) and Fibers (14%).

The AFP unit makes chemicals including coatings and inks additives and adhesives resins for a number of end-use markets including transportation, consumables, building and construction, energy, personal and home care.





The Advanced Materials segment makes polymers, films and plastics for transportation, consumables, building and construction, durable goods, and health and wellness markets.

The Chemical Intermediates unit sells intermediates, plasticizers and functional amines to markets such as industrial chemicals and processing, building and construction and agrochemicals.

The Fibers segments markets products such as acetate tow, acetate yarn and acetyl chemical products.



#### **Reasons To Sell:**

▼ While Eastman Chemical is seeing an end to customer inventory destocking across most of its end markets, it remains exposed to soft demand in building & construction and cautious customer behavior in consumer durables and electronics. Customers are increasingly cautious amid tariff-related uncertainties. Demand in building & construction remains sluggish in most regions, particularly China. The lower interest rate environment has not translated into a conducive environment for demand growth. Demand in the automotive space is expected to remain weak due to the decline in global automotive production. The impacts of weaker demand are likely to be seen in the company's top-line performance in 2025. The Advanced Materials and Additives & Functional Products segments face headwinds from the impacts of tariffs in China and the automotive markets.

Weak demand may hurt the company's volumes. It is also exposed to headwinds from higher energy costs. The Fibers unit also faces headwinds from destocking.

- ▼ Eastman Chemical faces challenges from higher energy costs in 2025. Higher energy costs, stemming from higher natural gas costs at its large sites in the United States. The company expects natural gas to be a \$50 million headwind in 2025. The company is also seeing higher raw material costs, partly due to higher costs of propane. Higher raw material and energy costs are expected to weigh on its margins.
- ▼ Customer inventory destocking in acetate tow is expected to continue to weigh on the Fibers unit in the fourth quarter. The company saw continued destocking in the third quarter and expects sustained destocking in the fourth quarter. This is expected to lead to lower volumes and profitability in the segment.
- ▼ The company faces headwinds from lower asset utilization in 2025. Roughly \$100 million headwind is expected in the second half of 2025 compared with the first half from lower asset utilization associated with aggressive inventory reductions in an uncertain demand environment. While these actions are expected to provide benefits in 2026, they are anticipated to weigh on the company's profitability in 2025.

## Risks<sup>(2)</sup> (to the Underperform recommendation)

- Eastman Chemical remains focused on growing new business revenues, leveraging its innovation-driven growth model. Its innovation and market development initiatives are expected to drive sales volumes in 2025. The company expects its specialty portfolio to drive sales growth across major markets such as consumer durables, building & construction, and transportation. Moreover, it achieved the successful start-up of the world's largest polyester recycling facility at its Kingsport site in the fourth-quarter of 2023. The company achieved strong operational performance at the Kingsport facility in the second quarter of 2025. The plant is expected to deliver roughly \$60-65 million of incremental EBITDA growth in 2025 compared with 2024 through the ramp-up of existing customers and new business wins. The company has also announced its plans to build the world's largest material-to-material molecular recycling facility in France, which is expected to be operational in 2026. The move is a key step in its efforts to accelerate its leadership in the circular economy.
- The company should gain from its strategic acquisitions. The acquisition of Solutia has offered excellent growth opportunities in Asia Pacific. Eastman Chemical expects to realize significant tax benefits from the acquisition. Moreover, the acquisition of BP Plc's aviation turbine engine oil business has enabled Eastman Chemical to better address the needs of the global aviation industry. Moreover, the purchase of Taminco Corporation has reinforced the company's foothold in attractive niche end-markets including food, feed and agriculture where Taminco has a strong presence. The acquisition has also provided attractive cost and revenue synergy opportunities. The acquisition of Premium Shield also expands the company's automotive base in North America, Europe and the Middle East and strengthens its paint protection film pattern development capabilities. The recent acquisition of a manufacturing facility in China also enables the company to be locally based and support clients in that country.
- Eastman Chemical is taking cost-cutting, productivity and price hike actions across its segments, especially for its specialty portfolio. This is helping it to offset raw material cost inflation and other cost headwinds. The company is taking a more aggressive approach toward cost management to keep its manufacturing and administrative costs in control. The company is making constant efforts to offset inflationary pressures and recover its margins. It expects cost and productivity actions to drive around \$75 million of earnings growth in 2025, with most of the benefits expected to be achieved in the second half. Additional cost savings of roughly \$100 million are expected in 2026 through the expanded program.
- The company remains focused on maintaining a disciplined approach to capital allocation, with an emphasis on financing its dividend and debt reduction. It returned more than \$700 million to shareholders in 2024 through dividends and share repurchases, including \$300 million of share buybacks. Eastman Chemical returned \$146 million to shareholders through dividends and share repurchases in the third quarter. It expects to repurchase shares worth around \$100 million in 2025. Eastman also increased its dividend for the 15th consecutive year. Furthermore, the company expects to deliver around \$1 billion in operating cash flow in 2025.

## **Last Earnings Report**

#### Eastman Chemical's Q3 Earnings and Sales Miss on Weaker Demand

Eastman Chemical logged third-quarter 2025 earnings of 40 cents per share, a roughly 74% decline from the year-ago quarter's figure of \$1.53.

The company posted adjusted earnings of \$1.14 per share, down from the year-ago quarter figure of \$2.26. It lagged the Zacks Consensus Estimate of \$1.18.

The company's revenues in the third quarter were roughly \$2.2 billion, down around 10.6% year over year. It missed the Zacks Consensus Estimate of \$2.24 billion.

Earnings Reporting Date	Nov 03, 2025
Sales Surprise	-1.79%
EPS Surprise	-3.39%
Quarterly EPS	1.14

12/31/2024

6.52

**FY Quarter Ending** 

Annual EPS (TTM)

Eastman Chemical's significant challenges continued in the third quarter. The company took actions to reduce inventory and focus better on cash generation, disciplined capital allocation, and structural cost reduction.

#### **Segment Highlights**

**Advanced Materials:** Sales from the segment fell 7% year over year to \$728 million in the reported quarter. The figure missed our estimate of \$742.1 million. Sales revenues declined due to lower sales volume and mix resulting from weak demand in high-value consumer discretionary end markets.

**Additives & Functional Products:** Sales from the segment were \$716 million, reflecting a decline of 4% from the year-ago quarter. The figure missed our estimate of \$735.4 million. Sales were dampened by lower sales volume due to the timing of heat transfer fluid project completions and continued weak demand in the building and construction and auto refinish end markets.

**Chemical Intermediaries:** Sales from the segment were down 16% year over year to \$499 million. The figure missed our estimate of \$514.4 million. Sales declined due to 8 percent lower sales volume and mix from continued weak market demand in the North American building and construction end market.

**Fibers:** The segment reported sales of \$254 million, down 24% year over year. The figure lagged our estimate of \$286.8 million. Sales declined primarily due to lower sales volume and mix as a result of lower acetate tow volume.

#### **Financials**

The company ended the quarter with cash and cash equivalents of \$489 million. Net debt was roughly \$4.59 billion.

Cash provided by operating activities was \$402 million, up around 1.5% year over year.

Eastman Chemical returned \$146 million to shareholders through dividends and share repurchases in the reported quarter.

#### Guidance

Eastman Chemical noted that it is seeing a challenging global macroeconomic environment. Customers are increasingly cautious due to a changing tariff environment and soft demand. The company expects to gain from the ramp-up of cost-reduction initiatives and higher revenues from its Kingsport methanolysis facility. The company aims to cut over \$75 million in costs this year and roughly \$100 million in 2026, with lower shutdown expenses and slightly better plant efficiency.

Eastman Chemical sees full-year adjusted earnings to be \$5.40-\$5.65 per share. It also expects to generate an operating cash flow of around \$1 billion for the full year.

## **Valuation**

Eastman Chemical's shares are down 44.1% over the trailing 12-month period. Over the past year, the Zacks Chemical - Diversified industry and the Zacks Basic Materials sector are down 37.2% and up 6.7%, respectively.

The S&P 500 index is up 12.3% in the past year.

The stock is currently trading at 6.46X trailing 12-month enterprise value-to EBITDA (EV/EBITDA) ratio, which compares to 10.84X for the Zacks sub-industry, 13.54X for the Zacks sector and 17.91X for the S&P 500 index.

Over the past five years, the stock has traded as high as 14.19X and as low as 4.68X, with a 5-year median of 7.75X.

Our Underperform recommendation indicates that the stock will perform below the market. Our \$50 price target reflects 8.12X forward 12-month earnings per share.

The table below shows summary valuation data for EMN:

Valuation Multiples - EMN										
		Stock	Sub-Industry	Sector	S&P 500					
	Current	6.46	10.84	13.54	17.91					
EV/EBITDA TTM	5-Year High	14.19	12.79	14.68	22.4					
	5-Year Low	4.68	5.56	5.75	13.87					
	5-Year Median	7.75	9.84	10.83	17.94					
	Current	9.53	19.05	14.94	22.8					
P/E F 12M	5-Year High	15.11	19.85	16.68	23.81					
	5-Year Low	7.36	8.82	8.03	15.73					
	5-Year Median	10.86	14.6	12.87	21.21					
	Current	1.15	1.32	3.23	8.19					
P/B TTM	5-Year High	2.85	3.12	4.25	9.16					
	5-Year Low	1.1	1.26	2.18	6.6					
	5-Year Median	2	2.01	3.03	8.03					

As of 11/24/2025

Source: Zacks Investment Research

## Industry Analysis<sup>(1)</sup> Zacks Industry Rank: Bottom 15% (204 out of 243)

#### ···· Industry Price 240 - .... Industry — Price 100 – 2021

## Top Peers (1)

Company (Ticker)	Rec	Rank
Akzo Nobel NV (AKZOY)	Neutral	3
Albemarle Corporatio(ALB)	Neutral	3
Air Products and Che(APD)	Neutral	3
Arkema SA (ARKAY)	Neutral	3
BASF SE (BASFY)	Neutral	3
Dow Inc. (DOW)	Neutral	3
Olin Corporation (OLN)	Neutral	3
DuPont de Nemours, I(DD)	Underperform	5

Industry Comparison <sup>(1)</sup>	Industry Comparison <sup>(1)</sup> Industry: Chemical - Diversified						
	EMN	X Industry	S&P 500	APD	DD	DOV	
Zacks Recommendation (Long Term)	Underperform	-	-	Neutral	Underperform	Neutra	
Zacks Rank (Short Term)	4	-	-	3	5	3	
VGM Score	D	-	-	D	С	<u> </u>	
Market Cap	7.25 B	2.59 B	38.78 B	53.41 B	17.29 B	16.53 l	
# of Analysts	6	3	22	7	3		
Dividend Yield	5.29%	1.76%	1.39%	2.98%	1.94%	6.02%	
Value Score	Α	-	-	С	С	В	
Cash/Price	0.07	0.16	0.04	0.03	0.22	0.2	
EV/EBITDA	6.46	6.28	14.61	51.22	7.47	5.5	
PEG Ratio	-0.90	2.55	2.19	2.36	1.98	N/	
Price/Book (P/B)	1.24	1.05	3.32	3.08	0.74	0.8	
Price/Cash Flow (P/CF)	5.08	6.34	15.20	12.58	5.93	3.9	
P/E (F1)	11.47	15.43	19.70	18.52	12.47	N/	
Price/Sales (P/S)	0.80	0.63	3.10	4.44	1.38	0.4	
Earnings Yield	8.56%	5.94%	5.07%	5.40%	8.02%	-4.43%	
Debt/Equity	0.82	0.56	0.56	0.98	0.30	0.9	
Cash Flow (\$/share)	12.50	3.19	8.99	19.07	6.95	5.8	
Growth Score	F	-	-	С	С	D	
Hist. EPS Growth (3-5 yrs)	-1.75%	-10.83%	8.16%	9.33%	2.37%	-39.07%	
Proj. EPS Growth (F1/F0)	-29.78%	-10.30%	8.50%	7.65%	-18.67%	N	
Curr. Cash Flow Growth	14.20%	0.55%	6.86%	0.55%	-17.47%	-2.56%	
Hist. Cash Flow Growth (3-5 yrs)	-2.07%	-1.87%	7.43%	6.86%	-16.60%	-5.70%	
Current Ratio	1.76	1.96	1.19	1.38	2.00	1.9	
Debt/Capital	45.02%	35.74%	38.01%	49.41%	23.19%	48.16%	
Net Margin	7.75%	0.48%	12.78%	-3.28%	-6.17%	-2.77%	
Return on Equity	12.89%	5.89%	17.00%	15.18%	7.81%	-2.25%	
Sales/Assets	0.60	0.74	0.53	0.30	0.34	0.7	
Proj. Sales Growth (F1/F0)	-6.20%	0.00%	5.81%	4.40%	-44.80%	-6.90%	
Momentum Score	F	-	-	С	D	F	
Daily Price Chg	-0.92%	-0.10%	0.88%	-1.55%	1.85%	0.95%	
1 Week Price Chg	-2.40%	-0.95%	0.10%	-1.25%	0.81%	-2.96%	
4 Week Price Chg	6.77%	6.15%	3.51%	-6.76%	7.06%	4.77%	
12 Week Price Chg	1.36%	-3.24%	2.87%	-10.05%	-45.84%	1.31%	
52 Week Price Chg	-30.73%	-18.08%	15.24%	-18.66%	-46.61%	-41.76%	
20 Day Average Volume	1,744,639	176,441	3,013,825	1,933,980	5,032,220	11,595,90	
(F1) EPS Est 1 week change	-0.97%	0.00%	0.00%	0.00%	0.00%	-4.02%	
(F1) EPS Est 4 week change	-1.40%	0.00%	0.00%	-0.11%	0.00%	-4.02%	
(F1) EPS Est 12 week change	-10.86%	-6.38%	0.69%	0.49%	-37.29%	-18.60%	
(Q1) EPS Est Mthly Chg	-8.94%	-0.29%	0.00%	0.08%	-1.07%	-0.70%	

## Analyst Earnings Model<sup>(2)</sup>

## Eastman Chemical Company (EMN)

In \$MM, except per share data

	2022A	2023A	2024A			2025E					2026E			2027E
	FY	FY	FY	1QA	2QA	3QA	4QE	FY	1QE	2QE	3QE	4QE	FY	FY
FY End's December 31st	Dec-22	Dec-23	Dec-24	31-Mar-25	30-Jun-25	30-Sep-25	31-Dec-25	Dec-25	31-Mar-26	30-Jun-26	30-Sep-26	31-Dec-26	Dec-26	Dec-27
Income Statement														
Sales	\$10,580.0	\$9,210.0	\$9,382.0	\$2,290.0	\$2,287.0	\$2,202.0	\$2,020.2	\$8,799.2	\$2,137.7	\$2,251.5	\$2,247.0	\$2,122.6	\$8,758.8	\$9,428.4
Cost of Sales	\$8,443.0	\$7,149.0	\$7,092.0	\$1,723.0	\$1,781.0	\$1,769.0	\$1,666.4	\$6,939.4	\$1,640.9	\$1,706.6	\$1,755.9	\$1,675.3	\$6,778.7	\$7,292.6
Gross Profit	\$2,137.0	\$2,061.0	\$2,290.0	\$567.0	\$506.0	\$433.0	\$353.8	<b>\$1</b> ,859.8	\$496.8	<b>\$</b> 544.9	\$491.1	\$447.3	\$1,980.1	\$2,135.7
Selling, General and Administrative Expenses	\$726.0	\$727.0	\$736.0	\$182.0	\$157.0	\$160.0	\$161.7	\$660.7	\$172.0	\$168.4	\$162.9	\$175.2	\$678.5	\$726.6
Research and Development Expenses	\$264.0	\$239.0	\$250.0	\$67.0	\$67.0	\$63.0	\$55.4	\$252.4	\$57.4	\$60.4	\$61.0	\$58.5	\$237.3	\$259.0
Asset Impairments and Restructuring Charges, Net	\$52.0	\$37.0	\$51.0	\$9.0	\$13.0	\$20.0	\$15.8	\$57.8	\$12.7	\$4.3	\$15.9	\$13.5	\$46.4	\$54.8
Other Components of Post-Employment (Benefit) Cost, Net	(\$101.0)	\$41.0	(\$72.0)	(\$1.0)	(\$2.0)	(\$1.0)	(\$4.1)	(\$8.1)	(\$2.7)	(\$2.9)	(\$2.5)	(\$4.0)	(\$12.2)	(\$32.4)
Other (Income) Charges, Net	(\$6.0)	\$38.0	\$47.0	\$8.0	\$49.0	\$3.0	(\$1.7)	\$58.3	\$9.7	\$30.5	\$5.2	\$0.4	\$45.8	\$51.4
Net (Gain) Loss on Divested Businesses	\$43.0	(\$323.0)	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0
Adjusted EBITDA	\$1,816.0	\$1,595.0	\$1,807.0	\$437.0	\$402.0	\$339.0	\$286.5	\$1,464.5	\$338.5	\$398.8	\$419.4	\$373.2	\$1,530.0	\$1,728.8
Depreciation and Amortization	\$477.0	\$498.0	\$509.0	\$126.0	\$127.0	\$129.0	\$128.1	\$510.1	\$120.0	\$120.1	\$122.1	\$123.3	\$485.6	\$527.9
Operating Income, Adjusted	\$1,339.0	\$1,097.0	\$1,298.0	\$311.0	\$275.0	\$210.0	\$158.4	\$954.4	\$218.5	\$278.7	\$297.3	\$249.8	<b>\$1</b> ,044.3	\$1,200.8
Operating Income, GAAP	\$1,159.0	\$1,302.0	\$1,278.0	\$302.0	\$222.0	\$188.0	\$126.8	\$838.8	\$247.8	\$284.2	\$248.5	\$203.8	\$984.3	\$1,076.3
Interest Expense	\$188.0	\$225.0	\$216.0	\$53.0	\$56.0	\$56.0	\$40.1	\$205.1	\$66.2	\$67.4	<b>\$</b> 65.9	\$51.8	\$251.3	\$261.2
Interest Income	\$6.0	\$10.0	\$16.0	\$4.0	\$3.0	\$2.0	\$2.7	\$11.7	\$3.4	\$3.2	\$2.6	\$2.8	\$12.0	\$13.8
Net Interest Expense	\$182.0	\$215.0	\$200.0	\$49.0	\$53.0	\$54.0	\$37.4	\$193.4	\$62.8	\$64.2	\$63.3	\$48.9	\$239.3	\$247.4
Pre-Tax Income, Adjusted	\$1,157.0	\$882.0	\$1,098.0	\$262.0	\$222.0	\$156.0	\$121.0	\$761.0	\$155.7	\$214.5	\$234.0	\$200.9	\$805.0	\$953.4
Pre-Tax Income, GAAP	\$977.0	\$1,087.0	\$1,078.0	\$253.0	\$169.0	\$134.0	\$89.4	\$645.4	\$184.9	\$220.0	\$185.2	\$154.8	\$745.0	\$828.9
Income Tax, Adjusted	\$170.0	\$117.0	\$164.0	\$39.0	\$36.0	\$24.0	\$19.4	\$118.4	\$24.9	\$34.3	\$37.4	\$32.1	\$128.8	\$152.5
Income Tax, GAAP	\$181.0	\$191.0	\$170.0	\$70.0	\$29.0	\$87.0	\$58.1	\$244.1	\$120.2	\$143.0	\$120.4	\$100.6	\$484.2	\$538.8
Tax Rate, Adjusted	15.0%	13.0%	15.0%	16.0%	16.0%	16.0%	16.0%	15.6%	16.0%	16.0%	16.0%	16.0%	16.0%	16.0%
Tax Rate, GAAP	19.0%	18.0%	16.0%	28.0%	17.0%	65.0%	65.0%	37.8%	65.0%	65.0%	65.0%	65.0%	65.0%	65.0%
Net Income	\$796.0	\$896.0	\$908.0	<b>\$1</b> 83.0	\$140.0	\$47.0	\$31.3	\$401.3	\$64.7	\$77.0	\$64.8	\$54.2	\$260.7	\$290.1
Non-Controlling Interests	\$3.0	\$2.0	\$3.0	\$1.0	\$0.0	\$0.0	\$0.0	\$1.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0
Net Income, Adjusted	\$984.0	\$763.0	\$931.0	\$222.0	\$186.0	\$132.0	\$101.7	\$641.7	\$130.8	\$180.2	<b>\$1</b> 96.5	\$168.8	\$676.2	\$800.9
Net Income, GAAP	\$793.0	\$894.0	\$905.0	\$182.0	\$140.0	\$47.0	\$31.3	\$400.3	\$64.7	\$77.0	\$64.8	\$54.2	\$260.7	\$290.1
Basic Shares Outstanding	123.5	118.6	116.7	115.2	115.0	114.4	113.6	114.6	112.8	112.1	111.3	110.5	111.7	108.6
Diluted Shares Outstanding	124.9	119.4	117.9	116.5	116.2	115.4	114.6	115.7	113.8	113.1	112.3	111.5	112.7	109.6
Basic EPS	\$6.42	\$7.54	\$7.75	\$1.58	\$1.22	\$0.41	\$0.28	\$3.49	\$0.57	\$0.69	\$0.58	\$0.49	\$2.33	\$2.67
Diluted EPS, Adjusted	\$7.88	\$6.40	\$7.89	\$1.91	\$1.60	\$1.14	\$0.89	\$5.54	\$1.15	\$1.59	\$1.75	\$1.51	\$6.01	\$7.31
Diluted EPS, GAAP	\$6.35	\$7.49	\$7.67	\$1.57	\$1.20	\$0.40	\$0.27	\$3.44	\$0.57	\$0.68	\$0.58	\$0.49	\$2.31	\$2.65
Dividend per Share	\$3.07	\$3.18	\$3.26	\$0.83	\$0.83	\$0.83	\$0.86	\$3.35	\$0.86	\$0.86	\$0.86	\$0.88	\$3.45	\$3.55

## **Zacks Stock Rating System**

We offer two rating systems that take into account investors' holding horizons: Zacks Rank and Zacks Recommendation. Each provides valuable insights into the future profitability of the stock and can be used separately or in combination with each other depending on your investment style.

#### **Zacks Recommendation**

The Zacks Recommendation aims to predict performance over the next 6 to 12 months. The foundation for the quantitatively determined Zacks Recommendation is trends in the company's estimate revisions and earnings outlook. The Zacks Recommendation is broken down into 3 Levels; Outperform, Neutral and Underperform. Unlike many Wall Street firms, we have an excellent balance between the number of Outperform and Neutral recommendations. Our team of 70 analysts are fully versed in the benefits of earnings estimate revisions and how that is harnessed through the Zacks quantitative rating system. But we have given our analysts the ability to override the Zacks Recommendation for the 1200 stocks that they follow. The reason for the analyst over-rides is that there are often factors such as valuation, industry conditions and management effectiveness that a trained investment professional can spot better than a quantitative model.


#### **Zacks Rank**

The Zacks Rank is our short-term rating system that is most effective over the one- to three-month holding horizon. The underlying driver for the quantitatively-determined Zacks Rank is the same as the Zacks Recommendation, and reflects trends in earnings estimate revisions.

### **Zacks Style Scores**

The Zacks Style Score is as a complementary indicator to the Zacks rating system, giving investors a way to focus on the highest rated stocks that best fit their own stock picking preferences.

Academic research has proven that stocks with the best Value, Growth and Momentum characteristics outperform the market. The Zacks Style Scores rate stocks on each of these individual styles and assigns a rating of A, B, C, D and F. We also produce the VGM Score (V for Value, G for Growth and M for Momentum), which combines the weighted average of the individual Style Scores into one score. This is perfectly suited for those who want their stocks to have the best scores across the board.



As an investor, you want to buy stocks with the highest probability of success. That means buying stocks with a Zacks Recommendation of Outperform, which also has a Style Score of an A or a B.

## **Disclosures**

This report contains independent commentary to be used for informational purposes only. The analysts contributing to this report do not hold any shares of this stock. The analysts contributing to this report do not serve on the board of the company that issued this stock. The EPS and revenue forecasts are the Zacks Consensus estimates, unless otherwise indicated in the report's first-page footnote. Additionally, the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts' personal views as to the subject securities and issuers. ZIR certifies that no part of the analysts' compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analyst in the report.

Additional information on the securities mentioned in this report is available upon request. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. Any opinions expressed herein are subject to change.

ZIR is not an investment advisor and the report should not be construed as advice designed to meet the particular investment needs of any investor. Prior to making any investment decision, you are advised to consult with your broker, investment advisor, or other appropriate tax or financial professional to determine the suitability of any investment. This report and others like it are published regularly and not in response to episodic market activity or events affecting the securities industry.

This report is not to be construed as an offer or the solicitation of an offer to buy or sell the securities herein mentioned. ZIR or its officers, employees or customers may have a position long or short in the securities mentioned and buy or sell the securities from time to time. ZIR is not a broker-dealer. ZIR may enter into arms-length agreements with broker-dealers to provide this research to their clients. Zacks and its staff are not involved in investment banking activities for the stock issuer covered in this report.

ZIR uses the following rating system for the securities it covers. **Outperform-** ZIR expects that the subject company will outperform the broader U.S. equities markets over the next six to twelve months. **Neutral-** ZIR expects that the company will perform in line with the broader U.S. equities markets over the next six to twelve months. **Underperform-** ZIR expects the company will underperform the broader U.S. equities markets over the next six to twelve months.

No part of this report can be reprinted, republished or transmitted electronically without the prior written authorization of ZIR.